Association Between Lipoprotein(a) and Long-term Outcomes after Percutaneous Coronary Intervention for Lesions with In-stent Restenosis
Percutaneous coronary intervention (PCI) with stent implantation is the most common therapeutic option for patients with obstructive coronary artery disease (CAD). The major drawback of this procedure is in-stent restenosis (ISR), due to biological, mechanical or other mechanisms. Despite the development of new-generation drug-eluting stents (DES), intervention of ISR consistently accounts for about 10% of overall PCI procedures,1 Management of ISR depends on underlying patient-, lesion-related mechanism and procedural-related risk factors for ISR, including diabetes mellitus, hypercholesterolemia, anatomic complexity, ste...
Source: Journal of Clinical Lipidology - May 18, 2023 Category: Lipidology Authors: Han Zhang, Yin Zhang, Tao Tian, Tianjie Wang, Jue Chen, Jinqing Yuan, Jie Qian, Fenghuan Hu, Kefei Dou, Shubin Qiao, Yongjian Wu, Changdong Guan, Bo Xu, Weixian Yang, Lei Song Tags: Original Research Source Type: research
Is hypertriglyceridemia a reliable indicator of cholesterol-depleted apoB particles?
In 2019, based on evidence from prospective observational studies, mendelian randomization analyses, and randomized clinical trials, the European Society of Cardiology/European Atherosclerosis (ESC/EAS) guidelines concluded that apoB is a more accurate measure of the cardiovascular risk due to the apoB lipoprotein particles than LDL cholesterol (LDL-C) or non-high density lipoprotein cholesterol (non-HDL-C).1 Since then, the evidence has grown even stronger with additional mendelian randomization studies demonstrating that apoB includes the cardiovascular risk attributable to triglycerides, LDL-C and even HDL-C and identif...
Source: Journal of Clinical Lipidology - May 12, 2023 Category: Lipidology Authors: Davide De Marco, Karol Pencina, Michael Pencina, Line Dufresne, George Thanassoulis, Allan D. Sniderman Tags: Original Research Source Type: research
An update on the first recorded case of familial hypercholesterolaemia: the Charioteer of Delphi
Since my first report that the Charioteer of Delphi, a bronze statue dating to the fifth century BCE, is the earliest representation of heterozygous familial hypercholesterolaemia (HeFH)1, evidence that his Achilles tendon swellings really are xanthomata has strengthened. Whilst many other bronzes of athletes from the same period were melted down during the vicissitudes of history2, some still exist, such as the Riace Bronzes, the Artemision Bronze, the Boxer at Rest and Ephebe of Marathon or marble copies (a cheaper material at the time), such as Discobolus and Hermes of Praxiteles. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - May 7, 2023 Category: Lipidology Authors: Paul N. Durrington Tags: Letter to the Editor Source Type: research
News from NLA
(Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - May 1, 2023 Category: Lipidology Source Type: research
Editorial Board
(Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - May 1, 2023 Category: Lipidology Source Type: research
Table of Contents
(Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - May 1, 2023 Category: Lipidology Source Type: research
From the editor: Transition of leadership for JCL
The Journal of Clinical Lipidology will move forward with new leadership in its next issue. I'm delighted to announce that P. Barton Duell, M.D., and Kevin C. Maki, Ph.D., will serve as Co-Editors-in-Chief (co-EICs). (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - May 1, 2023 Category: Lipidology Authors: John R. Guyton Source Type: research
In memoriam, Avedis Khachadurian 1926 - Sept 22,2022
It is with great respect, fondness, and admiration that I remember Avedis Khachadurian. I only had episodic interaction with Professor Khachadurian, but he left a strong impression and I wanted to share my thoughts with the lipidology community. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 29, 2023 Category: Lipidology Authors: Daniel Soffer Tags: Editorial Source Type: research
The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability worldwide and is expected to remain so beyond 2040 1. In China, cardiovascular disease (CVD) is the leading cause of death and is responsible for 40% of deaths in the Chinese population 2. One unique feature of the CVD in Chinese patient population is that the burden of ASCVD has rapidly and substantially increased, therefore, effective treatment of ASCVD should be considered a top priority for prevention of CVD in China 2. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 29, 2023 Category: Lipidology Authors: Zhu Luo, Zhijun Huang, Feng Sun, Fang Guo, Yingying Wang, Sheena Kao, Guoping Yang, Jie HuangPharm, Jiaxin Li, Sylvia Zhao, YanLing He Source Type: research
Evidence regarding SGLT-2 inhibitors for the management of diabetic dyslipidemia
We thank doctors Seetharaman and Joshi for their interest in our recently published Expert Consensus Statement on Management of Diabetic Dyslipidemia in Indians from the Lipid Association of India.1 They have expressed concerns about possible adverse effects of treatment with sodium-glucose cotransporter-2 (SGLT2) inhibitors on the concentration of low-density lipoprotein cholesterol (LDL-C) in plasma. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 28, 2023 Category: Lipidology Authors: P. Barton Duell, Raman Puri, Vimal Mehta, Nathan D. Wong Tags: Letter to the Editor Source Type: research
APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia
ApoC-III is a protein produced in the liver and intestine and enriched in triglyceride-rich lipoproteins (TRLs), including chylomicrons.1, 2 ApoC-III increases plasma triglyceride levels primarily by inhibiting lipoprotein lipase activity and slowing hepatic uptake of triglyceride-rich lipoproteins (TRLs). Hypertriglyceridemia is associated with non-alcoholic fatty liver disease (NAFLD).3 However, there are no approved therapies to treat NAFLD and it is unclear whether triglyceride lowering, particularly with drugs capable of reducing plasma levels by>70%, affects pre-existing hepatic steatosis in patients with severe hype...
Source: Journal of Clinical Lipidology - April 26, 2023 Category: Lipidology Authors: Thomas A. Prohaska, Veronica J. Alexander, Ewa Karwatowska-Prokopczuk, Joseph Tami, Shuting Xia, Joseph L. Witztum, Sotirios Tsimikas Tags: Brief Communication Source Type: research
Effect of pharmacologic anti-atherosclerotic therapy on carotid intraplaque neovascularization: a systematic review
Atherosclerotic cardiovascular (CV) disease is one of the leading causes of global mortality. It is a progressive inflammatory disease that involves lipid accumulation in the sub-intimal layer of the arterial wall, resulting in gradual plaque formation1. Plaque rupture is implicated in a large proportion of major adverse cardiovascular events (MACE), including acute coronary syndrome and ischemic stroke. The presence of intraplaque neovascularization (IPN) in large arterial plaques have been associated with an increased risk of rupture and plaque vulnerability. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 26, 2023 Category: Lipidology Authors: Edward Cui, Georgia Kersche, Nicholas Grubic, Marie-France H étu, Stephen C. Pang, Henrik Sillesen, Amer M. Johri Tags: Review Article Source Type: research
Evidence regarding SGLT2 inhibitors for the management of diabetic dyslipidemia
We read with interest the article by Puri et al. entitled, “Management of diabetic dyslipidemia in Indians: Expert consensus statement from the Lipid Association of India”. The article states that more than half of the patients with diabetes have a high risk of dyslipidemia, resulting in an accelerated risk of atherosclerotic cardiovascular disease (ASC VD). The authors thereby release a consensus statement from the Lipid Association of India (LAI) for the management of diabetic dyslipidemia. This statement discusses the effects of lipid lowering drugs such as statins/ezetimibe, sodium-glucose transport protein 2 (SGL...
Source: Journal of Clinical Lipidology - April 25, 2023 Category: Lipidology Authors: Rajmohan Seetharaman, Shirish S. Joshi Tags: Letter to the Editor Source Type: research
Lipid treatment status and goal attainment among patients with premature acute coronary syndrome in Israel
The management of dyslipidemias constitutes a key target in decreasing the risk of morbidity and mortality among patients after acute coronary syndrome (ACS)1,2. Both the 2018 American College of Cardiology/American Heart Association / Multi-society (2018 ACA/AHA/MS) Guidelines and the European Society of Cardiology (ESC) Dyslipidemia Guidelines consider individuals with established coronary artery disease at high risk for future cardiovascular events and recommend intensive lipid-lowering strategies for them3,4. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 21, 2023 Category: Lipidology Authors: Feras Haskiah, Abid Khaskia Tags: Original Research Source Type: research
Maternal triglyceride levels and neonatal outcomes: the Japan Environment and Children's Study
Intrauterine exposures and maternal health status influence the neonatal outcomes such as low birth weight, preterm birth and small for gestational age. The mother's nutrition and metabolism are major determinants of fetal growth1,2. Previous studies suggest that the maternal lipid profiles during pregnancy may provide an additional source of energy to the fetus, potentially influencing fetal adiposity and growth. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 20, 2023 Category: Lipidology Authors: Hayato GO, Koichi HASHIMOTO, Hajime MAEDA, Kei OGASAWARA, Hyo KYOZUKA, Tsuyoshi MURATA, Akiko SATO, Yuka OGATA, Kosei Shinoki, Hidekazu NISHIGORI, Keiya FUJIMORI, Seiji YASUMURA, Mitsuaki HOSOYA Tags: Original Research Source Type: research
